Natco Pharma rose 1.90% to Rs 908 after the drug maker launched its Everolimus tablets in 10 mg strength in the US market.
Everolimus is a generic version of Afinitor tablets, used to treat certain types of cancers, tumors, and seizures.According to industry sales data, the 10 mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021.
On a consolidated basis, Natco Pharma's net profit dropped 38.6% to Rs 75 crore on 27.2% fall in net sales to Rs 410.30 crore in Q1 June 2021 over Q1 June 2020.
Natco Pharma manufactures a comprehensive range of branded and generic dosage forms, bulk actives and intermediates for both Indian as well as International markets.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
